reMYND announces publication in Alzheimer’s and Dementia on pivotal role of cytosolic calcium in Alzheimer’s disease

  • Home
  • /
  • About us
  • /
  • News
  • /
  • reMYND announces publication in Alzheimer’s and Dementia on pivotal role of cytosolic calcium in Alzheimer’s disease

Leuven Belgium, 3 May 2023: reMYND NV, a clinical stage company addressing neurodegeneration, is pleased to announce the publication of a review article in this month’s edition of Alzheimer’s and Dementia, exploring the role of calcium dyshomeostasis in driving neurodegeneration in dementia, particularly Alzheimer’s disease (AD).

The article, entitled Cytosolic calcium: judge, jury and executioner of neurodegeneration in Alzheimer’s disease and beyond, provides a conceptual framework as to how a wide variety of AD risk factors promote the onset and progression of neurodegeneration through calcium dyshomeostasis.

AD is a heterogenous disease triggered by a multitude of different risk factors such as ageing, stress, cardiovascular disease and traumatic brain injury. Despite the diversity of initial triggers, the disease ultimately progresses to common disease outcomes such as cognitive decline, plaques and tangles. A prominent topic in the field relates as to the nature of common AD processes. Addressing this question is important because treatments targeting these processes might have the potential to reverse disease progression throughout the heterogeneous patient population. 

The article concludes that dysregulated calcium homeostasis is a common pathway across AD, linking the major features of the disease. Consequently, therapeutic options that restore calcium homeostasis safely should have a robust neuroprotective potential, not only to counter symptoms but also to halt or delay ongoing neuronal demise in patients through disease modification. In order to fully test the hypothesis, treatments are needed that address calcium homeostasis in a safe way.

The full article can be accessed here:

Prof. Grace Stutzmann, Discipline Chair of Neuroscience at the Chicago Medical School, and Co-Author of the article added: We are very proud of this collaborative work which documents the rich research history of calcium dysregulation in neurodegenerative disease, and provides a thorough overview of the mechanisms by which calcium dyshomeostasis leads in a progressive manner to AD.  Furthermore, the complementary strengths of industry and academic perspectives contributes to the unique and up-to-date nature of this review, highlighting the exciting therapeutic potential of targeting calcium channels for AD.”

Dr Gerard Griffioen Chief Scientific Officer of reMYND and Co-Author of the article said: “Through this comprehensive review of research to date, we outline a clear connection between as to how AD risk factors impair calcium homeostasis to drive neurodegeneration in Alzheimer’s disease. This understanding of the disease’s pathway is capitalized in reMYND’s Alzheimer’s ongoing clinical program, which seeks to address the disease at its root.”




About Alzheimer’s and Dementia

Alzheimer’s & Dementia®, the Journal of the Alzheimer’s Association with a Journal Impact Factor (Clarivate) of 16.655, aims to bridge the knowledge gaps across a wide range of bench-to-bedside investigation in dementia and Alzheimer's Disease.


About reMYND

reMYND is a clinical stage company developing novel treatments for Alzheimer’s, Huntington’s, epilepsy, ALS and other neurodegenerative diseases caused by neuronal dysfunction. It is backed by a proprietary drug discovery platform, which enables the identification of novel mechanisms-of-action, targets and first-in-class small molecules.

reMYND’s most advanced program is ReS19-T, an investigational compound for the treatment of Alzheimer’s currently in Phase 2a. Similarly, reMYND’s Huntington program fully restores cortico-striatal transmission and regenerates the mouse brain in the standard Huntington knock-in mice.

In addition, reMYND has a dedicated Contract Research Organization (CRO), which focuses on CNS disorders. The team helps clients to assess the pharmacokinetics, pharmacodynamics and efficacy of their experimental treatments in reMYND’s proprietary animal models. The CRO has a global client base, including the US, Europe and Japan.

reMYND was founded in 2002 as a spin-off from the University of Leuven, and has been substantially supported by grants from VLAIO/IWT (Flanders, Belgium). Find out more at